ViewRay To Participate in the 21st Annual Oppenheimer Healthcare Conference
ViewRay, Inc. (NASDAQ: VRAY) announced its participation in the 21st Annual Oppenheimer Healthcare Conference on March 16, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ViewRay, Inc. (NASDAQ: VRAY) announced its participation in the 21st Annual Oppenheimer Healthcare Conference on March 16, 2021. The company's management will conduct a virtual fireside chat at 3:50 PM ET and hold individual meetings with investors. A live webcast will be available on ViewRay's investor website, with a replay accessible for seven days following the event. ViewRay is known for its MRIdian® radiation therapy system, which is designed to tackle unique challenges in advanced radiation oncology.
Details
News Market Reaction – VRAY
The recorded move for VRAY in the trading session of this news was +5.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, March 5, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) (the "Company") today announced that members of management will be participating in the 21st Annual Oppenheimer Healthcare Conference on Tuesday, March 16, 2021. ViewRay will be conducting a virtual fireside chat at 3:50 PM ET, as well as hosting 1x1 meetings with investors.
A live webcast of the Company's fireside chat will be available on the "Financial Events and Webinars" section of ViewRay's investor website at: https://investors.viewray.com/events-and-presentations/upcoming-events. A replay of the presentation will be available for the following 7 days.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
View original content:http://www.prnewswire.com/news-releases/viewray-to-participate-in-the-21st-annual-oppenheimer-healthcare-conference-301241544.html
SOURCE ViewRay, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.